AOD-9604 Research Protocols & Administration Dosing in Published Research Research investigations have employed diverse AOD-9604 doses across species and administration routes: Rodent studies: 250-500 mcg/kg orally or intraperitoneally was most common for obesity research Rabbit models: 0.25 mg per joint for osteoarthritis studies (intra-articular injection) Pig pharmacokinetic studies: 1.5 mg/kg IV and 2 mg/kg oral for metabolism characterization Human clinical trials: Oral doses of 0.25-10 mg daily
This remains an actively moving area, however: on February 27, 2026, the HHS Secretary publicly announced an intent to move roughly 14 of the 19 Category 2-listed peptides, reportedly including ipamorelin and CJC-1295, back toward Category 1 status, and multiple industry and legal-news outlets reported further FDA action in the following months easing Category 2-related restrictions on this group of peptides
Definition and diagnostic criteria Gamma-glutamyl transpeptidase deficiency is a very rare autosomal recessive disease characterized by increased glutathione concentration in plasma and urine
It increases the expression of growth factors, like VEGF and FGF, which are essential for tissue regeneration
Use our peptide dosage calculator guide for precise concentration calculations
Once inside the enterocytes, B12 is released from intrinsic factor and binds to transcobalamin II, forming holotranscobalamin, the biologically active form that enters the bloodstream